CVRXHealthcare · Medical DevicesThe 7 Wall Street analysts covering CVRx, Inc. hold a median 12-month price target of $4.5 — +56.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores CVRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (78): Smaller than most of the companies we track.
Momentum (9): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CVRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +56.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $13 → $5.00 |
| 8 Aug 2026 | Lake Street | Downgrade | Hold | — |
| 7 Aug 2026 | Lake Street | Downgrade | Hold | $14 → $3.50 |
| 14 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 14 Apr 2026 | Canaccord Genuity | Maintains | Buy | $10 |
| 13 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 Nov 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 5 Aug 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 9 May 2025 | JP Morgan | Downgrade | Underweight | — |
| 9 May 2025 | Piper Sandler | Maintains | Overweight | — |
| 8 Apr 2025 | Canaccord Genuity | Maintains | Buy | — |
| 8 Apr 2025 | Lake Street | Maintains | Buy | — |
| 5 Feb 2025 | Canaccord Genuity | Maintains | Buy | — |
| 5 Feb 2025 | Piper Sandler | Maintains | Overweight | — |
| 17 Jan 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 Jan 2025 | William Blair | Upgrade | Outperform | — |
| 9 Dec 2024 | Canaccord Genuity | Maintains | Buy | — |
| 4 Nov 2024 | Craig-Hallum | Maintains | Buy | — |
| 30 Oct 2024 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CVRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, CVRx, Inc. returned −65.0% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 65% of US stocks
Cheaper than 27% of US stocks
Cheaper than 69% of US stocks
Higher than 63% of US stocks
Higher than 53% of US stocks
Higher than 95% of US stocks
Higher than 15% of US stocks
Higher than 7% of US stocks
Higher than 10% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CVRx, Inc. has a market value of $76.7M and an enterprise value of $71.5M.
Revenue in the twelve months to 30 June 2026: $61.2M. The latest quarter grew 15.6% year on year.
Net income over the same four quarters: −$52.0M, a −84.9% net margin.
Diluted earnings per share, trailing twelve months: $−1.98.
Free cash flow in the twelve months to 30 June 2026: −$41.1M.
Trailing P/E: −1.4×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.
CVRx, Inc. employs 223 people — $274K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CVRx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
CVRx has secured Devoted Health Medicare Advantage coverage for its Barostim therapy, expanding reimbursement access to approximately 466,000 members across 29 states.
Why it matters — Expanded insurance coverage could widen patient access to Barostim, potentially supporting broader adoption of CVRx's therapy.
CVRx issued a statement in response to a public letter dated August 24, 2026, sent to its Board of Directors by Jorey Chernett of Pointillist Family Office. The company said its Board and leadership remain committed to acting in the best interests of all shareholders and regularly evaluate a full range of options to maximize shareholder value.
Why it matters — The shareholder letter and CVRx's public response signal an active, open engagement between the company's board and an investor, which CVRx watchers would follow for potential governance or strategic developments.
Block & Leviton LLP is investigating CVRx, Inc. for potential securities law violations and is contacting investors who lost money in their CVRx investment to learn how they might recover those losses. The firm announced the inquiry on August 24, 2026.
Why it matters — CVRX watchers would care because the company is the subject of a securities law investigation that could indicate legal or regulatory exposure for the company.
CVRx announced that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. Devoted Health provides coverage to approximately 466,000 Medicare Advantage members across 29 states.
Why it matters — This new coverage policy may expand patient access to Barostim therapy through a major national Medicare Advantage insurer.
Jorey Chernett, founder of Pointillist Family Office and beneficial owner of more than 5.5% of CVRx's outstanding shares, delivered a letter to the company's board urging it to launch an immediate and formal process to sell the company to a strategic acquirer. The letter highlights the value proposition of CVRx's Barostim product to a larger medical device company with established infrastructure.
Why it matters — A significant shareholder is publicly pressing the board to begin a sale process, a development that could influence the company's strategic direction.
The 7 Wall Street analysts covering CVRx, Inc. have a median 12-month price target of $4.5, with estimates ranging from $3.5 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering CVRx, Inc., 3 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks CVRx, Inc. 33 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 11 Sept 2026, CVRx, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (78 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +56.3% from the last close, and Ticker Nerd's factor model ranks CVRx, Inc. 33 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CVRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.5 to $6 over the next 12 months.
CVRx, Inc. returned -65.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease.
The most recent item we track (Zacks Investment Research, 28 Aug 2026): "CVRx Secures Devoted Health Coverage for Barostim Therapy". CVRx has secured Devoted Health Medicare Advantage coverage for its Barostim therapy, expanding reimbursement access to approximately 466,000 members across 29 states.
CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular disease. Its flagship product, Barostim, is an implantable therapy system that delivers electrical pulses to carotid baroreceptors to help regulate autonomic nervous system activity and support cardiovascular function. The company’s current offerings center on Baroreflex Activation Therapy, a minimally invasive treatment approach used for patients with heart failure and other cardiovascular conditions. CVRx develops, manufactures, and commercializes its products in the United States, Germany, and selected international markets through direct sales and distribution channels. Headquartered in Minneapolis, Minnesota, CVRx plays a specialized role in the medical technology market by providing device-based therapies that address complex cardiac care needs.
CEO Mr. Kevin Hykes · 223 employees · United States · https://www.barostim.com
